Compare GORO & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | IVVD |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.9M | 437.1M |
| IPO Year | 2010 | 2021 |
| Metric | GORO | IVVD |
|---|---|---|
| Price | $1.38 | $1.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.75 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 2.4M | 1.8M |
| Earning Date | 04-16-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,726,000.00 | $53,426,000.00 |
| Revenue This Year | $9.04 | $143.48 |
| Revenue Next Year | $93.07 | $25.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $0.34 | $0.46 |
| 52 Week High | $1.87 | $3.07 |
| Indicator | GORO | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 57.32 |
| Support Level | $1.27 | $1.41 |
| Resistance Level | $1.75 | $2.01 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 10.67 | 96.00 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.